Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.54 |
| ▸ | MPO | P05164 | 8/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8125191 | 0.92 | SLC6A4 (0.84) | SLC6A4MAPK1GPR84MPOHTR2A | |
| SCHEMBL4828133 | 0.90 | SLC6A4 (0.56) | SLC6A4MAPK1GPR84HTR2AHTR1A | |
| SCHEMBL4821123 | 0.86 | SLC6A4 (0.74) | SLC6A4MAPK1GPR84MPOHTR2A | |
| SCHEMBL5726056 | 0.83 | SLC6A4 (1.00) | SLC6A4MAPK1GPR84MPOHTR2A | |
| SCHEMBL26996488 | 0.83 | SLC6A4 (0.83) | SLC6A4MAPK1GPR84MPOHTR2A | |
| SCHEMBL8655091 | 0.81 | HTR1A (0.60) | GPR84HTR2ATRPM8HTR1ATSHR | |
| SCHEMBL31302667 | 0.81 | SLC6A4 (0.68) | SLC6A4GPR84KMT2ABCHE | |
| SCHEMBL31302691 | 0.81 | SLC6A4 (0.68) | SLC6A4GPR84KMT2ABCHE | |
| SCHEMBL30877187 | 0.80 | HTR6 (0.67) | SLC6A4MAPK1GPR84HTR2A | |
| SCHEMBL29206564 | 0.80 | HTR6 (0.67) | SLC6A4MAPK1GPR84HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7419986-B2 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| US-7335666-B2 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | WYETH (US) | 2008-02-26 | — | — | US | disclosed |
| US-20070004702-A1 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | WYETH (US) | 2007-01-04 | — | — | US | disclosed |
| US-20060293301-A1 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | WYETH (US) | 2006-12-28 | — | — | US | disclosed |
| US-7135479-B2 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | WYETH (US) | 2006-11-14 | — | — | US | disclosed |
| CN-1701076-A | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | WYETH CORP (US) | 2005-11-23 | — | — | CN | disclosed |
| US-20040132714-A1 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | WYETH | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293301-A1 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | CRH, HTR5A, DBH | SLC6A4 216/4885MAPK1 3811/4885GPR84 361/4885 |
| US-20070004702-A1 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | CRH, CYP19A1, HTR5A | SLC6A4 263/4885MAPK1 3523/4885GPR84 382/4885 |
| US-20040132714-A1 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | CYP19A1, CRH, CYP17A1 | SLC6A4 278/4885MAPK1 2795/4885GPR84 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.